论文部分内容阅读
探讨苯二氮 艹卓 受体拮抗剂 氟马西尼治疗昏迷的临床价值。结果表明 :氟马西尼治疗后 15 ,30 ,6 0和 180minMGCS得分较治疗前依次增加 5 3,8 0 ,9 4和 7 3分 ,较常规药物组分别增加 5 2 ,7 7,8 7和 6 9分 (P <0 .0 1)。治疗后OAA/S得分也较治疗前增加 1 9分 (P <0 .0 1)。治疗过程中除少数患者出现轻度激越现象和窦性心动过速外 ,未发现其它副作用。提示氟马西尼能有效地拮抗因急性苯二氮 艹卓 类药物中毒而引起的意识障碍 ,具有较好的抗昏迷作用
To investigate the clinical value of flunitinib in the treatment of coma by benzodiazepine receptor antagonist. The results showed that the scores of MGCS at 15, 30, 60 and 180 min after flumazenil treatment were increased by 53, 80, 94 and 73, respectively, compared with those before treatment, which were respectively 5.27 and 8.77 And 69 points (P <0.01). After treatment, OAA / S scores also increased by 19 compared with pre-treatment (P <0.01). In addition to a few patients during treatment mild agitation and sinus tachycardia, no other side effects were found. It is suggested that flumazenil can effectively antagonize the disturbance of consciousness caused by acute benzodiazepine poisoning and has better anti-coma effect